Jaguar Health Targets Global Expansion for Canalevia®

Jaguar Health, Inc. is making strides to broaden the application of Canalevia® (crofelemer delayed-release tablets) for the treatment of general diarrhea in dogs, beyond its current use for chemotherapy-induced diarrhea (CID). Currently conditionally approved by the FDA, Canalevia aims to address a large gap in veterinary medicine as no FDA-approved treatment exists for general diarrhea in dogs.

At the upcoming 2025 Animal Health Summit in Kansas City, Jaguar will be seeking collaborations with potential partners to achieve U.S. and European market approvals. The company prioritizes finding the optimal partner to fund and commercialize Canalevia's development globally. The expansion could significantly impact the market, with over 11 million dogs in the U.S. suffering from general diarrhea annually.

The company also shared updates on its ongoing field study for Canalevia-CA1, aimed at achieving full FDA approval. The study is 25% enrolled, suggesting promising progress toward meeting regulatory requirements. Jaguar plans to submit supporting data to European authorities, possibly securing EU marketing rights.